Adrenal Cortical Adenocarcinoma

Adrenal cortical carcinoma (ACC) is a rare, fast-growing cancer that starts in the outer layer of the adrenal gland (the cortex). The adrenal cortex makes important hormones such as cortisol (stress hormone), aldosterone (salt and blood pressure control), and androgens/estrogens (sex hormones). In ACC, abnormal cells grow without control and can make too many hormones. This extra hormone production may cause signs like Cushing’s syndrome (from high cortisol), high blood pressure and low potassium (from too much aldosterone), or excess hair growth, acne, deep voice, or irregular periods (from extra androgens), or breast growth in men (from estrogens). Some tumors do not make hormones and grow silently until they are big. ACC can spread to nearby tissues, liver, lung, lymph nodes, or bone. The main treatment is complete surgical removal. Medicines such as mitotane and chemotherapy are often added. Care is best in a specialist center with a team that includes endocrine surgeons, medical oncologists, endocrinologists, radiologists, and pathologists.

Doctors most often use the name adrenocortical carcinoma (ACC) for a cancer that starts in the adrenal cortex, the outer layer of the adrenal gland. The adrenal cortex makes important hormones, such as cortisol, aldosterone, and androgens (testosterone-like hormones). When a malignant tumor grows from these cells, it is aggressive and can spread to nearby tissues and to distant organs like the liver, lungs, or bones. Some tumors make extra hormones and cause strong body changes (for example, Cushing’s syndrome or virilization). Other tumors do not make hormones and stay “silent” until they are large. The exact cause is often unknown, but some inherited gene changes increase risk. Diagnosis uses hormone testing and imaging. Surgery is the main treatment when possible. Medicines and radiation may be used when surgery cannot remove all cancer or when it comes back.

Another names

The preferred medical name is adrenocortical carcinoma (ACC). Older or less precise terms include adrenal cortical carcinoma, adrenal cortex carcinoma, and sometimes (incorrectly) adrenal cortical adenocarcinoma. (“Adenoma” means benign; “carcinoma” means malignant.) When the tumor makes too much cortisol it may be called ACTH-independent Cushing’s syndrome due to ACC. Tumors that produce androgens have been called virilizing adrenal carcinoma. In children, the name pediatric adrenocortical carcinoma is used.

Types

By hormone activity

• Functional ACC: The tumor makes extra hormones. It can cause Cushing’s syndrome (too much cortisol), hyperaldosteronism (too much aldosterone), or androgen/estrogen excess (sex-hormone effects).

• Nonfunctional ACC: The tumor does not make hormones. Symptoms usually come from the mass itself (pain, fullness) or from spread.

By stage (ENSAT system)

• Stage I–II: Tumor confined to the adrenal gland (smaller vs larger).

• Stage III: Tumor has grown into nearby tissues/lymph nodes.

• Stage IV: Distant spread (liver, lungs, bone, etc.).

By microscopic features

• Low-grade vs high-grade based on criteria like Weiss score and Ki-67 index (how fast cells divide). Higher scores mean more aggressive behavior.

By age group

• Pediatric ACC (rare, sometimes linked to inherited TP53 variants).

• Adult ACC (most cases; slight female predominance).

Causes

The exact cause is usually unknown. Below are 20 factors that are known risks, associations, or biological changes commonly found in ACC. I will label them clearly and explain briefly.

1. Germline TP53 mutation (Li-Fraumeni syndrome)
   A hereditary change in the TP53 “guardian” gene greatly increases cancer risk, including ACC, especially in children. The abnormal p53 protein cannot properly repair DNA or stop damaged cells from multiplying.

2. Beckwith–Wiedemann spectrum (11p15 imprinting defects)
   Children with this overgrowth syndrome have changes near the IGF2 gene region that promote cell growth and raise ACC risk.

3. Familial adenomatosis polyposis–related variants (rare association)
   Some families with APC gene problems have reported adrenal tumors; ACC is rare but reported.

4. MEN1 (multiple endocrine neoplasia type 1) – occasional association
   MEN1 mainly causes other endocrine tumors, but adrenal cortical tumors, including rare ACC, can occur.

5. Congenital adrenal hyperplasia (CAH) – chronic stimulation
   Long-term ACTH drive and adrenal hyperplasia may set a background for abnormal growth; true ACC is uncommon but reported.

6. Somatic TP53 mutations in the tumor
   Even without inherited risk, many ACC tumors acquire TP53 mutations that drive malignant behavior.

7. IGF2 overexpression
   A hallmark of many ACCs. Too much IGF2 promotes cell growth and survival.

8. Wnt/β-catenin pathway activation (CTNNB1 mutations)
   Abnormal signaling makes cells divide and resist normal controls.

9. Mismatch repair defects (rare)
   When DNA repair is faulty, mutations accumulate; rare ACCs show this pattern.

10. MEN1 gene alterations in the tumor
    Loss of menin function in adrenal cells can contribute to neoplasia.

11. Chromosomal instability (gains/losses on 5, 7, 12, 17, 19, 20)
    Copy-number changes disturb growth-control genes.

12. Epigenetic dysregulation (DNA methylation changes)
    Chemical tags on DNA get altered and switch key growth genes on/off in the wrong way.

13. Prior abdominal radiation (possible risk)
    Radiation can damage DNA and rarely lead to adrenal malignancies years later.

14. Environmental carcinogens (uncertain, suspected)
    Long-term exposure to some toxins may increase general cancer risk; specific links to ACC remain weak.

15. Chronic inflammation/oxidative stress in adrenal tissue
    Stressed cells accumulate DNA damage over time, which can set the stage for cancer.

16. Long-standing hormonal imbalance and growth signals
    Persistent growth signals (e.g., ACTH drive) may promote abnormal clones, though ACC is still rare.

17. Impaired apoptosis (cell self-destruction) pathways
    When “suicide” programs fail, damaged adrenal cells survive and multiply.

18. Angiogenic switch (VEGF upregulation)
    Tumors learn to grow their own blood supply, helping them expand and spread.

19. Immune evasion (tumor microenvironment changes)
    Cancer cells avoid immune attack by altering surface markers and local signals.

20. Age and female sex (epidemiology)
    ACC occurs at any age but has peaks in childhood and mid-adult years, with a slight female predominance; these patterns may reflect hormonal or genetic influences.

Symptoms and signs

1. Abdominal or flank pain
   A growing mass stretches tissues or presses on nerves.

2. Fullness or a lump in the belly
   Large tumors can be felt or noticed as swelling.

3. Unexplained weight loss and fatigue
   Cancer uses energy; appetite can fall, and the body breaks down muscle and fat.

4. Cushing’s syndrome features (from high cortisol)
   Round face, central weight gain, thin skin, easy bruising, purple stretch marks, acne, mood changes, poor wound healing.

5. High blood pressure
   From excess cortisol or aldosterone, or from kidney blood vessel compression.

6. Low potassium (muscle cramps, weakness)
   Excess aldosterone makes the kidneys waste potassium.

7. New or worsening diabetes or glucose intolerance
   Cortisol raises blood sugar, making diabetes harder to control.

8. Proximal muscle weakness
   High cortisol breaks down protein, making climbing stairs or rising from chairs hard.

9. Excess hair growth and acne in women (hirsutism)
   Androgen-producing tumors cause coarse hair on face/chest and severe acne.

10. Deepening voice, menstrual irregularity, infertility
    Androgen excess disrupts normal female hormone balance.

11. Gynecomastia in men
    Some tumors make estrogen; breast tissue can enlarge and become tender.

12. Decreased libido or impotence in men
    Hormone imbalance and overall illness can affect sexual function.

13. Bone fragility and fractures
    Cortisol weakens bone, leading to osteoporosis.

14. Mood swings, depression, sleep problems
    Cortisol and chronic illness affect brain chemistry and sleep cycles.

15. Symptoms from spread (metastases)
    Cough or shortness of breath (lungs), right-upper-belly pain (liver), bone pain or fractures (bone).

Diagnostic tests

I will group tests by category. Each item explains what it is and why it matters.

Physical examination (bedside observations)

1. General exam with vital signs
   Blood pressure, pulse, temperature, and weight give quick clues—high blood pressure and weight changes can suggest hormone excess.

2. Cushingoid features check
   Doctor looks for round face, central obesity, thin skin, bruises, and purple stretch marks. These signs point to cortisol excess from a functional tumor.

3. Hirsutism and virilization assessment
   Pattern of hair growth, acne, scalp hair thinning, deep voice, and clitoromegaly help identify androgen-producing tumors.

4. Edema and heart/lung exam
   Fluid retention, crackles, or heart changes can appear with severe hormone excess or metastases.

5. Abdominal palpation
   Sometimes a large adrenal mass can be felt. Tenderness or fullness guides imaging urgency.

“Manual” clinical tests (simple bedside or office measures)

6. Blood pressure profile (including orthostatics)
   Multiple readings and standing/supine measurements help confirm hypertension and volume status seen in aldosterone or cortisol excess.

7. Manual muscle testing
   Checks for proximal muscle weakness typical of Cushing’s syndrome.

8. Skin inspection and wound-healing check
   Thin skin, bruises, and slow healing support cortisol excess.

9. Ferriman–Gallwey scoring (visual scoring for hirsutism)
   A standardized, manual scoring chart helps document androgen effects.

10. Waist circumference and body-fat pattern
    Central fat accumulation supports hypercortisolism; it also helps track treatment results.

Laboratory and pathological tests

11. Overnight 1-mg dexamethasone suppression test
    You take dexamethasone at night; morning cortisol is measured. Failure to suppress suggests autonomous cortisol production.

12. 24-hour urinary free cortisol
    Collecting urine for a day measures total cortisol production. High levels confirm hypercortisolism.

13. Late-night salivary cortisol
    Cortisol should be low at night. A high value supports Cushing’s syndrome.

14. Plasma aldosterone concentration and renin ratio
    A high aldosterone-to-renin ratio points to autonomous aldosterone production (primary hyperaldosteronism).

15. Serum androgens/estrogens (DHEA-S, androstenedione, testosterone, estradiol)
    Markedly high adrenal androgens (or estrogen in some cases) suggest a functional adrenal cortex tumor.

16. Electrolytes, kidney and liver panels, fasting glucose/HbA1c
    Low potassium, high glucose, and abnormal liver tests help assess hormone effects and spread.

17. Plasma or urine metanephrines (to exclude pheochromocytoma before biopsy)
    Rule out adrenal medulla tumors that can cause dangerous blood pressure spikes during procedures.

18. Pathology with Weiss score and Ki-67 index (after surgery or biopsy when appropriate)
    The pathologist confirms carcinoma and estimates aggressiveness. Ki-67 shows how fast cells divide; higher numbers predict a tougher course.

19. Immunohistochemistry (SF-1, inhibin-α, Melan-A, calretinin)
    These markers confirm adrenal cortical origin. They help distinguish ACC from metastases from other organs.

20. Molecular profiling (when available)
    Testing for TP53, CTNNB1, and other alterations refines prognosis and may open trial options. IGF2 overexpression is common.

Electrodiagnostic tests (supportive)

• Electrocardiogram (ECG)
  Low potassium from aldosterone excess can cause specific ECG changes (U waves, arrhythmias). ECG also checks overall heart health before surgery.

• Ambulatory blood pressure monitoring (selected cases)
  A 24-hour device records blood pressure patterns and confirms true hypertension linked to hormone excess.

(Electrodiagnostic studies are not central to diagnosing ACC itself, but they are useful to evaluate the effects of hormone excess on the heart and to ensure safe care.)

Imaging tests

• Adrenal-protocol CT scan (with contrast)
  Key first imaging. It shows tumor size, shape, invasion, and spread. Features like irregular borders, necrosis, and high unenhanced density suggest carcinoma.

• MRI of the adrenal (chemical-shift and contrast sequences)
  Helps separate benign adenoma from carcinoma and shows invasion of vessels or nearby organs.

• FDG PET/CT
  Cancer cells often take up more sugar. PET helps stage disease, find hidden spread, and monitor response.

• Chest CT
  Looks for lung metastases, which are common in advanced ACC.

• Liver imaging (MRI or contrast CT)
  Checks for liver spread when blood tests or symptoms raise suspicion.

• Bone scan or PET for bone pain
  Finds bone metastases when symptoms or labs suggest it.

• Iodocholesterol (NP-59) scintigraphy (rarely used now)
  Older functional scan that shows steroid-producing tissue. Mostly historical, but you may still read about it.

• Adrenal venous sampling (select cases of aldosterone excess)
  More common for primary aldosteronism from adenomas, but occasionally used in complex hormone cases to localize secretion.

• Biopsy—only in specific situations
  Usually avoided when imaging and hormones already point to ACC, because biopsy has limited value and a small risk of tumor seeding. If the diagnosis is unclear and metastasis from another cancer is suspected, a carefully planned biopsy after ruling out pheochromocytoma may be done.

Non-Pharmacological Treatments

Physiotherapy & Physical Rehabilitation

1. Prehabilitation program (before surgery or chemo)
   Description: A 2–6-week plan of gentle aerobic activity, light resistance, breathing drills, and nutrition optimization before treatment.
   Purpose: Build reserve to handle surgery/chemo better.
   Mechanism: Improves lung function, muscle strength, and heart fitness; lowers complications.
   Benefits: Fewer post-op issues, faster recovery, less fatigue.

2. Graduated walking plan
   Description: Daily step goals that slowly rise (for example, +500 steps per week).
   Purpose: Fight cancer-related fatigue and deconditioning.
   Mechanism: Boosts mitochondrial function, circulation, and mood neurochemicals.
   Benefits: Better stamina, sleep, and appetite.

3. Low-impact aerobic training (cycling/elliptical/swimming)
   Description: 20–30 minutes, 3–5 days/week at easy–moderate intensity.
   Purpose: Maintain heart-lung fitness during treatment.
   Mechanism: Increases VO₂ capacity; reduces inflammatory cytokines.
   Benefits: Less dyspnea on exertion, improved energy.

4. Progressive resistance training
   Description: 2–3 sessions/week using bands or light weights for major muscle groups.
   Purpose: Preserve muscle mass lost from cortisol excess and chemo.
   Mechanism: Stimulates muscle protein synthesis; counteracts catabolism.
   Benefits: Strength, balance, independence, glucose control.

5. Diaphragmatic breathing & inspiratory muscle training
   Description: Slow belly breathing; device-based inspiratory exercises.
   Purpose: Reduce anxiety and improve post-op lung function.
   Mechanism: Parasympathetic activation; stronger respiratory muscles.
   Benefits: Calmer mind, fewer lung complications.

6. Thoraco-lumbar mobility and core stability
   Description: Gentle spinal mobility, pelvic tilts, plank variants.
   Purpose: Relieve back/abdominal discomfort, support posture.
   Mechanism: Improves spinal mechanics and deep core activation.
   Benefits: Less pain, better movement, safer lifting.

7. Balance and gait training
   Description: Single-leg stance, tandem walk, wobble board with support.
   Purpose: Prevent falls in weak or dizzy patients.
   Mechanism: Trains vestibular and proprioceptive systems.
   Benefits: Confidence and safety in daily tasks.

8. Flexibility & fascia care
   Description: Daily stretching of hips, hamstrings, chest; foam-rolling.
   Purpose: Reduce stiffness from inactivity or steroids.
   Mechanism: Increases tissue glide and joint range.
   Benefits: Easier movement, lower injury risk.

9. Pelvic floor & cough-support drills
   Description: Coordinated pelvic floor engagement with exhalation and bracing.
   Purpose: Protect core and incision sites after abdominal surgery.
   Mechanism: Improves pressure management.
   Benefits: Less post-op discomfort, safer mobilization.

10. Post-op early mobilization
    Description: Sitting up day 0–1; short hallway walks with supervision.
    Purpose: Speed gut recovery and prevent clots/pneumonia.
    Mechanism: Activates gut motility and circulation.
    Benefits: Shorter hospital stay, fewer complications.

11. Lymphedema/edema self-management (as needed)
    Description: Elevation, gentle compression if prescribed, massage by trained therapist.
    Purpose: Control swelling after lymph node dissection.
    Mechanism: Supports lymph return, reduces fluid buildup.
    Benefits: Comfort, better range of motion.

12. Cancer-related fatigue pacing
    Description: Plan activities with rest blocks; prioritize “must-do” tasks.
    Purpose: Prevent energy crashes.
    Mechanism: Matches energy supply and demand.
    Benefits: More stable energy and control.

13. Pain-neuroscience education + graded exposure
    Description: Learn how pain circuits work; gradually re-introduce feared moves.
    Purpose: Reduce fear-avoidance cycles.
    Mechanism: Retrains brain threat systems.
    Benefits: Less pain sensitivity, more function.

14. Sleep hygiene coaching
    Description: Fixed wake time, light in morning, screen curfew, cool dark bedroom.
    Purpose: Improve sleep disturbed by hormones, stress, steroids.
    Mechanism: Resets circadian rhythm.
    Benefits: Better mood, appetite, healing.

15. Return-to-work/role rehab
    Description: Stepwise work hardening; task simulation; ergonomics.
    Purpose: Safe, realistic return to daily roles.
    Mechanism: Builds task-specific tolerance.
    Benefits: Confidence, quality of life, income stability.

Mind-Body, “Gene/Genetics,” and Educational Therapies (10)

16. Mindfulness-based stress reduction (MBSR)
    Purpose: Lower anxiety/depression; improve pain coping.
    Mechanism: Calms stress axis (HPA), reduces inflammatory signaling.
    Benefits: Better mood, sleep, and treatment adherence.

17. Cognitive behavioral therapy (CBT)
    Purpose: Reframe catastrophic thoughts; manage insomnia and procedure fear.
    Mechanism: Structured thought-behavior change.
    Benefits: Less distress, clearer decision-making.

18. Yoga or Tai Chi (gentle forms)
    Purpose: Combine breath, balance, and calm movement.
    Mechanism: Parasympathetic activation; muscle-joint conditioning.
    Benefits: Flexibility, mood, fall prevention.

19. Guided imagery & music therapy
    Purpose: Ease nausea, pain, and anxiety during chemo or scans.
    Mechanism: Competes with pain pathways; relaxes limbic system.
    Benefits: More comfort; less antiemetic use in some.

20. Peer support group / survivorship coaching
    Purpose: Reduce isolation; share coping and resources.
    Mechanism: Social buffering lowers stress hormones.
    Benefits: Hope, practical tips, resilience.

21. Onco-nutrition education
    Purpose: Meet protein/calorie needs; handle steroid-related glucose swings.
    Mechanism: Tailored meal planning with RD.
    Benefits: Weight and muscle protection; safer blood sugars.

22. Genetic counseling (TP53/Li-Fraumeni, BWS, MMR)
    Purpose: Check inherited risk; guide family testing and surveillance.
    Mechanism: Interprets gene results; sets screening plans.
    Benefits: Early detection for family; tailored care.

23. Treatment navigation education
    Purpose: Understand surgery, mitotane, chemo, scans, and timelines.
    Mechanism: Teach-back with plain-language handouts.
    Benefits: Fewer surprises; better adherence and safety.

24. Medication interaction coaching
    Purpose: Prevent dangerous interactions (mitotane is a strong enzyme inducer).
    Mechanism: Pharmacist review of all meds and supplements.
    Benefits: Fewer side effects; drugs work as intended.

25. Financial and practical counseling
    Purpose: Plan for costs, transport, and time off.
    Mechanism: Link to assistance programs and workplace rights.
    Benefits: Less stress; continuous treatment.

---

Drug Treatments

(class, typical dose/timing, purpose, mechanism, key side effects—always individualized by your oncology team)

1. Mitotane (adrenolytic; cornerstone drug)
   Dose: Start ~1–2 g/day in divided doses; titrate (as tolerated) toward 3–6 g/day; target serum level often 14–20 mg/L; needs fatty meals.
   Purpose: Kill residual ACC cells; control hormone excess.
   Mechanism: Destroys adrenal cortical cells; induces CYP3A4 (many interactions).
   Side effects: Nausea, diarrhea, fatigue, dizziness, memory issues; adrenal insufficiency (often needs steroid replacement).

2. Etoposide (chemotherapy; part of EDP-M)
   Dose: Commonly 100 mg/m² IV days 2–4 in 28-day cycles with cisplatin+doxorubicin+mitotane.
   Purpose: Shrink or control advanced ACC.
   Mechanism: Topoisomerase II inhibitor → DNA breaks.
   Side effects: Low blood counts, hair loss, nausea.

3. Doxorubicin (anthracycline; EDP-M)
   Dose: ~40–50 mg/m² IV day 1 per cycle; lifetime dose limited.
   Purpose: Part of multi-drug cytotoxic therapy.
   Mechanism: Intercalates DNA; free-radical damage.
   Side effects: Low counts, mucositis, heart toxicity (monitor).

4. Cisplatin (platinum; EDP-M)
   Dose: ~40 mg/m² IV day 1–2 per cycle; aggressive hydration.
   Purpose: Backbone cytotoxic agent in ACC regimens.
   Mechanism: DNA crosslinking → apoptosis.
   Side effects: Nausea/vomiting, kidney toxicity, neuropathy, hearing loss.

5. Streptozocin (alkylating agent; alternative)
   Dose: Protocol-based IV; sometimes with mitotane.
   Purpose: Option if platinum regimen not suitable.
   Mechanism: Alkylates DNA, pancreas-islet tropism but active in ACC.
   Side effects: Nausea, kidney issues, low counts.

6. Temozolomide (oral alkylator; off-label in selected cases)
   Dose: 150–200 mg/m² orally days 1–5 of 28-day cycle.
   Purpose: Salvage therapy in progressing disease.
   Mechanism: DNA methylation at O6-guanine.
   Side effects: Fatigue, low counts, nausea.

7. Pembrolizumab (PD-1 inhibitor; immunotherapy)
   Dose: 200 mg IV q3 weeks or 400 mg q6 weeks.
   Purpose: For MSI-H/dMMR or TMB-high tumors; sometimes used after chemo.
   Mechanism: Unblocks T-cells to attack cancer.
   Side effects: Immune-related: thyroiditis, colitis, hepatitis, rash.

8. Nivolumab (PD-1 inhibitor)
   Dose: 240 mg IV q2 weeks or 480 mg q4 weeks; sometimes with ipilimumab.
   Purpose: Selected refractory cases; clinical-trial context preferred.
   Mechanism: Restores anti-tumor T-cell activity.
   Side effects: Immune-related toxicities similar to pembrolizumab.

9. Ipilimumab (CTLA-4 inhibitor; often with nivolumab)
   Dose: 1–3 mg/kg IV q3 weeks x4 in combo schemes.
   Purpose: Deepen immune activation in resistant disease.
   Mechanism: Blocks CTLA-4 brakes on T-cells.
   Side effects: Higher immune toxicities; requires close monitoring.

10. Metyrapone (steroidogenesis blocker)
    Dose: Often 500–750 mg orally 3–4×/day; adjust to cortisol levels.
    Purpose: Rapid control of Cushing’s syndrome from cortisol-secreting ACC.
    Mechanism: Inhibits 11β-hydroxylase → lowers cortisol.
    Side effects: Hypertension, acne/hirsutism (androgen shunt), GI upset.

11. Ketoconazole (antifungal; steroidogenesis inhibitor)
    Dose: 200–400 mg orally 2–3×/day; liver tests required.
    Purpose: Control cortisol when metyrapone/mitotane insufficient.
    Mechanism: Blocks CYP17 and other enzymes.
    Side effects: Liver toxicity, GI upset, many drug interactions.

12. Osilodrostat (11β-hydroxylase inhibitor)
    Dose: Start 1–2 mg twice daily; titrate to cortisol control.
    Purpose: Another option for Cushing’s control in expert hands.
    Mechanism: Potent 11β-hydroxylase block.
    Side effects: Adrenal insufficiency, QT prolongation, hypokalemia.

13. Mifepristone (glucocorticoid receptor blocker)
    Dose: 300–1200 mg/day orally.
    Purpose: Treats hyperglycemia and symptoms of Cushing’s when cortisol can’t be lowered.
    Mechanism: Blocks cortisol action at its receptor.
    Side effects: Endometrial thickening, low potassium, fatigue; interacts with many drugs.

14. Spironolactone (mineralocorticoid receptor blocker)
    Dose: 25–200 mg/day orally in divided doses.
    Purpose: Control blood pressure and potassium in aldosterone-secreting tumors; treat androgenic symptoms.
    Mechanism: Antagonizes aldosterone; weak antiandrogen.
    Side effects: High potassium, breast tenderness, menstrual changes.

15. Physiologic steroid replacement (Hydrocortisone ± Fludrocortisone)
    Dose: Hydrocortisone 15–25 mg/day in 2–3 doses; fludrocortisone 0.05–0.2 mg/day if needed.
    Purpose: Replace hormones when mitotane or surgery causes adrenal insufficiency.
    Mechanism: Replaces missing cortisol (± aldosterone effect).
    Side effects: If overdosed: weight gain, high BP; if underdosed: fatigue, low BP—dose is individualized.

Always discuss exact regimens and doses with your oncology team. Many of these drugs interact with mitotane and other medicines.

---

Dietary Molecular Supplements

(supportive only; not a cure—clear with your oncology team due to drug interactions, especially with mitotane)

1. High-quality protein (whey/pea isolate) – Dose: 20–30 g between meals. Function: Preserve lean mass during catabolic states. Mechanism: Leucine-triggered muscle protein synthesis.

2. Vitamin D₃ – Dose: 1000–2000 IU/day (individualized to levels). Function: Bone health; immune modulation, especially with steroid use. Mechanism: Nuclear receptor signaling supporting calcium balance.

3. Calcium citrate – Dose: 500–600 mg/day divided; adjust to diet and labs. Function: Protect bones under steroid exposure. Mechanism: Replenishes calcium with good absorption when gastric acid is low.

4. Omega-3 fatty acids (EPA/DHA) – Dose: 1–2 g/day combined EPA+DHA. Function: Help weight/appetite, anti-inflammatory support. Mechanism: Competes with arachidonic acid pathways; may reduce cachexia.

5. Soluble fiber (psyllium/β-glucan) – Dose: 5–10 g/day with water. Function: Gut regularity during opioids or steroid shifts; cholesterol aid. Mechanism: Increases stool bulk; binds bile acids.

6. Probiotics (Lactobacillus/Bifidobacterium blends) – Dose: per product; often 10⁹–10¹⁰ CFU/day. Function: Support microbiome during antibiotics/chemo. Mechanism: Competes with pathogens; strengthens gut barrier.

7. Magnesium – Dose: 200–400 mg/day (citrate/glycinate). Function: Muscle cramps, constipation relief, sleep support. Mechanism: Smooth muscle relaxation; enzyme cofactor.

8. Vitamin B12 ± Folate – Dose: B12 500–1000 µg/day; folate 400–800 µg/day if deficient. Function: Counter deficiency-related anemia/neuropathy. Mechanism: DNA synthesis and nerve myelin support.

9. Ginger extract – Dose: 500–1000 mg/day in divided doses. Function: Nausea support with chemo. Mechanism: 5-HT₃ and NK-1 modulation; pro-kinetic effects.

10. L-glutamine (oral) – Dose: 10 g twice daily (short term). Function: Mouth-sore and gut support in some chemo regimens. Mechanism: Fuel for enterocytes; mucosal repair.

Avoid St. John’s wort, high-dose grapefruit, and unverified “adrenal boosters”—they can interact with mitotane or chemo.

---

Immunity-Booster / Regenerative / Stem-Cell–Related” Drugs

There are no approved “stem-cell drugs” to treat ACC. Below are legitimate immune and hematologic support medicines used around cancer care. Do not use unapproved stem-cell products.

1. Pembrolizumab (PD-1 inhibitor) – see above dosing. Function: Activates immune system against tumors (MSI-H/TMB-high). Mechanism: Releases PD-1 brake on T-cells.

2. Nivolumab ± Ipilimumab – see above. Function: Broader immune activation in selected cases.

3. Filgrastim (G-CSF) – Dose: 5 µg/kg SC daily after chemo until count recovery. Function: Prevents/treats neutropenia. Mechanism: Stimulates bone-marrow stem cells to make neutrophils.

4. Pegfilgrastim – Dose: 6 mg SC once per chemo cycle. Function/Mechanism: Long-acting G-CSF.

5. Epoetin alfa or Darbepoetin – Dose: Protocol-based. Function: Treats chemo-related anemia when appropriate. Mechanism: Drives red-cell production from marrow progenitors.

6. Romiplostim or Eltrombopag (TPO receptor agonists) – Dose: Per protocol. Function: Selected use for low platelets with certain therapies. Mechanism: Stimulate megakaryocytes/platelets.

---

Surgeries

1. Open adrenalectomy with en-bloc resection
   Procedure: Remove the adrenal tumor through an open incision, often taking a margin of nearby fat/organ if stuck.
   Why: Best chance of cure when tumor is resectable; open approach lowers risk of tumor rupture.

2. Regional lymph node dissection
   Procedure: Remove nodes near the adrenal.
   Why: Staging accuracy and possible local control.

3. Vena cava tumor-thrombus thrombectomy (if tumor grows into IVC)
   Procedure: Vascular-assisted removal of tumor clot from the big abdominal vein.
   Why: Restore blood flow; achieve complete resection.

4. Metastasectomy (liver/lung) in select patients
   Procedure: Remove limited metastatic deposits.
   Why: In carefully chosen cases, can improve control and survival.

5. Laparoscopic/robotic adrenalectomy (highly selected small tumors)
   Procedure: Keyhole removal by experts following strict oncologic rules.
   Why: Faster recovery only when cancer biology and size suggest safety; many ACCs still require open surgery.

---

Prevention & Safety Strategies

(Primary prevention is limited; focus is on early detection, complication prevention, and recurrence reduction)

1. Genetic counseling/testing when family history or early-age tumor suggests a syndrome.

2. Expert center care to optimize surgery quality (complete resection lowers recurrence).

3. Regular follow-up imaging and hormone tests per guidelines to catch recurrence early.

4. Medication interaction checks (mitotane induces enzymes; adjust other drugs).

5. Vaccinations (flu, COVID-19, pneumococcal as indicated) before/around therapy to reduce infections.

6. Bone health plan if on steroids: calcium, vitamin D, weight-bearing exercise, bone-density checks.

7. Blood pressure, glucose, and potassium control when hormones are high.

8. DVT prevention during surgery/chemo: early walking, compression, and anticoagulants if indicated.

9. Avoid unnecessary radiation exposure and unproven “alternative cures.”

10. Healthy lifestyle basics: no tobacco, limit alcohol, maintain weight, sleep, and stress care.

---

When to See a Doctor Urgently

• Severe weakness, fainting, or very low blood pressure (possible adrenal crisis).

• Fever ≥38.0 °C (100.4 °F) during chemo or while counts are low.

• Sudden shortness of breath, chest pain, or leg swelling (possible clot).

• Severe abdominal pain, fast-growing mass, or vomiting.

• Uncontrolled high BP, very low potassium, or severe high blood sugars.

• New confusion, severe headache, or visual changes.

• Any rapid swelling, jaundice, or heavy bleeding.

---

What to Eat & What to Avoid

Prefer / Eat more of 

1. Protein with each meal (eggs, fish, chicken, tofu, lentils) to protect muscle.

2. Colorful vegetables and fruits for fiber and micronutrients.

3. Whole grains (oats, brown rice, quinoa) for steady energy.

4. Healthy fats (olive oil, nuts, seeds) to meet higher calorie needs.

5. Dairy or fortified alternatives for calcium and vitamin D.

6. Plenty of fluids, mainly water; add broths if appetite is low.

7. Small, frequent meals if early fullness or nausea.

8. Ginger or peppermint tea for queasiness.

9. Low-sodium choices if BP is high from hormones.

10. Food-safety focus: well-cooked proteins, washed produce (especially with low white counts).

Limit / Avoid:

• Alcohol (raises BP and interacts with meds).

• Grapefruit/Seville orange (drug interactions).

• High-salt foods if aldosterone excess causes hypertension/edema.

• Unpasteurized foods or raw seafood when counts are low.

• Herbal “adrenal boosters” or St. John’s wort (serious interactions).

---

Frequently Asked Questions

1. Is “adrenal cortical adenocarcinoma” the same as ACC?
   Yes—doctors use adrenocortical carcinoma (ACC) for the malignant tumor of the adrenal cortex.

2. What is the main treatment?
   Complete surgical removal by an expert team is the key when possible. Medicines like mitotane and chemotherapy often follow.

3. Can the tumor make hormones?
   Yes. Many ACCs make cortisol, aldosterone, or androgens/estrogens, causing distinct symptoms.

4. How is it staged?
   By ENSAT I–IV, based on size, local invasion, nodes, and spread.

5. What is mitotane and why is it special?
   It is an adrenolytic drug that targets adrenal cortex cells and helps prevent recurrence but has many side effects and interactions.

6. Is chemo always used?
   Not always. It’s used for high-risk disease, positive margins, or spread. EDP-M (etoposide/doxorubicin/cisplatin + mitotane) is common.

7. Does immunotherapy work?
   It may help selected tumors (e.g., MSI-H/dMMR/TMB-high). It is not a universal cure.

8. Can ACC be cured?
   Yes, sometimes, especially if caught early and completely removed. Advanced cases are harder but still treatable.

9. How often are scans after surgery?
   Often every 3–6 months for the first years, then less often (your team sets the exact plan).

10. What about radiation?
    Used for pain or local control when surgery isn’t possible or to treat metastases; not usually first-line cure.

11. Will I need hormone pills?
    Possibly, especially if one adrenal is removed or if on mitotane; hydrocortisone (± fludrocortisone) may be needed.

12. Are there warning signs of adrenal crisis?
    Severe fatigue, low BP, nausea/vomiting, confusion. It’s an emergency—carry steroid alert instructions.

13. Should my family get genetic testing?
    If your team suspects an inherited syndrome, a genetic counselor will guide testing for relatives.

14. Can diet or supplements cure ACC?
    No. Diet and supplements are supportive only. Always check for drug interactions.

15. Where should I get care?
    At a high-volume endocrine cancer center with experienced surgeons and an ACC-focused team.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 08, 2025.